Carl l. Gordon

Carl l. Gordon (board member) discloses dealings in 13 companies, chiefly ADARx Pharmaceuticals, Inc., Electra Therapeutics, Inc. and Theseus Pharmaceuticals, Inc. Over a trading history stretching from 12 October 2021 to 28 September 2026, the count stands at 53 filings.

The open-market side counts 23 purchases for €75.2M alongside 3 sales for €14.4M. Taken together, the purchases exceed the sales by €60.9M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 5 share grants. 2026 to date brings 7 purchases and no sales.

Half of the purchases are above €1.0M and half below. Of 23 purchases, 23 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 3 purchases with a full 90-day history, the hit rate stands at 67% and the median 90-day move at +3.6%. These figures describe past trades and do not predict future prices.

The latest filing, published on 30 September 2026, reports an open-market purchase of €918k in ADARx Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.